Established indications for allogeneic hematopoietic stem cell transplantation (alloSCT) in acute myeloid leukemia.
| Prognostic Subgroup . | First CR . | Second or Higher CR . |
|---|---|---|
| In all these conditions an allogeneic stem cell transplantation from a fully matched family donor is generally the first therapeutic option of choice. | ||
| † If a matched family donor is not available, an allotransplant from a matched unrelated donor as salvage therapy is the second choice in situations of high risk. | ||
| Abbreviations: CR, complete remission; AML, acute myeloid leukemia. | ||
| Favorable-risk AML | ||
| Acute promyelocytic leukemia | No | Yes† |
| Core binding factor AML | No | Yes† |
| Intermediate-risk AML | Yes | Yes† |
| Poor-risk AML | ||
| Age ≤ 60 years | Yes† | Yes† |
| Age > 60 years | Investigational | Investigational |
| Prognostic Subgroup . | First CR . | Second or Higher CR . |
|---|---|---|
| In all these conditions an allogeneic stem cell transplantation from a fully matched family donor is generally the first therapeutic option of choice. | ||
| † If a matched family donor is not available, an allotransplant from a matched unrelated donor as salvage therapy is the second choice in situations of high risk. | ||
| Abbreviations: CR, complete remission; AML, acute myeloid leukemia. | ||
| Favorable-risk AML | ||
| Acute promyelocytic leukemia | No | Yes† |
| Core binding factor AML | No | Yes† |
| Intermediate-risk AML | Yes | Yes† |
| Poor-risk AML | ||
| Age ≤ 60 years | Yes† | Yes† |
| Age > 60 years | Investigational | Investigational |